RegeneRative mediCine - ALM Events

Group Discount Offer
See Inside for Details!
6th Annual
Stem Cells&
Regenerative Medicine
The Annual Standard in Industry-Focused Applications of Stem Cell Research
Opening Keynote:
Shelly Heimfeld, Ph.D., Director of Cellular Therapy
and Cell Processsing Facilities Associate Member
Fred Hutchinson Cancer Research Center
President
the International Society of Cellular Therapy
Featured Sections Include:
4 Discovery Cells
4 Discovery-Enabling Materials
4 Pre-Clinical Development
4 Clinical Development
4 New Technologies
4 Commercialization and Investment Opportunities
4 Regulatory Issues
Platinum Sponsor:
Presentations By:
4 Advanced Cell Technology
4 Aggregate Therapeutics
4 Arteriocyte
4 Avlar BioVentures Ltd
4 Celgene
4 Cellerant Therapeutics
4 Center for Biologics Evaluation and
Research/US-FDA
4 Eli Lilly
4 Fred Hutchinson Cancer Research Center
4 Geron
4 Intercytex
4 Novocell, Inc.
4 Pfizer
4 Pittsburgh Lifesciences Greenhouse
4 Plasticell
4 Proteus Venture Partners
4 Q Therapeutics, Inc.
4 Reeve-Irvine Research Center
4 Repair Technologies
4 Rodman & Renshaw
4 Stem Cell Therapeutics Corp.
4 The Biologics Consulting Group, Inc
4 McGowan Institute for Regenerate
Medicine (MIRM) and The Pittsburgh Tissue
Engineering Initiative (PTEI)
4 University of Wisconsin - Madison
©2006 Strategic Research Institute. All rights reserved.
October 16-17, 2006 • Renaissance Pittsburgh Hotel • Pittsburgh, PA
To Register Call 800-599-4950 / 212-967-0095 or Visit www.srinstitute.com/stemcells

Welcome
Dear Colleague:
The promise of stem cells & regenerative medicine discoveries and their potential
to transform the treatment of disease, continues to drive biological research and
technology development in the life sciences. The fact that analysts predict that a
market based on stem cell therapies could grow anywhere from $10-30 billion by
2010 makes it crucial for us to gather and discuss the research and commercialization
activities currently being conducted by academia and industry. The field of
regenerative medicine is surrounded by hype, but successful commercialization
will depend on careful analysis of business strategies that can deliver hope to
patients.
Please join us in Pittsburgh, Pennsylvania, October 16-17, 2006 for the 6th Annual
Stem Cells & Regenerative Medicine meeting.
This forum is the perfect setting for thought leaders in regenerative medicine to
convene and share critical perspectives on the current status and future of stem
cell research and regenerative medicine. This meeting is designed to promote
interactions that will ultimately result in the acceleration of scientific discovery and
the development of new technologies, in the end benefiting patients worldwide.
We look forward to being your hosts in Pittsburgh for the second consecutive
year. Pittsburgh’s strengths in the areas of transplantation, tissue engineering and
stem cell research continue to make it a great location for us to come together for
the advancement of regenerative medicine.
Regards,
Dr. Doros Platika, Conference
Co-Chair, President & CEO
The Pittsburgh Life Sciences
Greenhouse
5
CALL:
(800) 599.4950
(212) 967.0095
8:30 - 5:30 Eastern Time
Monday – Friday
FAX:
(212) 967.8021
MAIL:
Return Registration Form to:
Strategic Research Institute
333 Seventh Avenue, 9th Floor
New York, NY 10001
E-MAIL:
info@srinstitute.com
WEB:
www.srinstitute.com/stemcells
Dr. Alan Russell, Conference
Co-Chair, Director, McGowan
Institute for Regenerative
Medicine (MIRM) and
Executive Director, The Pittsburgh
Tissue Engineering Initiative
(PTEI)
P.S. Register by September 1, 2006 and Save $300
Easy Ways To Register
Group Discount:
Group Discounts Available: If you send two delegates
to this conference at the full registration fee, the third and
subsequent delegates receive a $200 discount off the
conference registration fee.
PAYMENTS: $695 Academic/Government/Nonprofit; $1195
Early bird: until Friday September 1, 2006; $1495 After
September 1st and before October 6th; $1595 after October
6th
This includes all breakfasts, lunches, refreshments, receptions
and the conference documentation workbook. Payments
may be made by company check, American Express, Visa,
MasterCard or Diners Club. Please make checks payable
to: Strategic Research Institute L.P. and make sure to write
the registrant’s name on the face of the check along with the
conference code CS369. Payments are required fifteen (15)
business days prior to attendance at the seminar. If payment
has not been received prior to registration, a credit card hold
will be required and will be processed 2 weeks following the
seminar.
LIMITED NUMBERS: The number of participants is limited to
maximize the amount of personal involvement and feedback
you receive. During this seminar, you will have the opportunity
to try out techniques and take risks in a small group of your
colleagues, benefiting from expert guidance throughout the
day.
CANCELLATIONS: All cancellations will be subject to a
$227 administration fee. In order to receive a refund, your
notice of cancellation must be received in writing (by letter or
fax) no later than August 18, 2006. We regret that refunds
Scientific Advisory Board:
Gabriela Cezar, Ph.D., Associate
Professor
UNIVERSITY OF WISCONSIN -
MADISON
Karen Chandross, Ph.D., Head, Multiple
Sclerosis-Regeneration/Repair Group,
CNS Division
AVENTIS PHARMACEUTICALS
Annemarie Moseley, Ph.D.,
M.D. , Acting CEO, Aggregate
Therapeutics
Chairman, REPAIR TECHNOLOGIES
Doros Platika, M.D., Ph.D, President &
CEO
PITTSBURGH LIFE SCIENCES
GREENHOUSE
Dr. Alan Russell, Conference
Co-Chair, Director, McGowan Institute
for Regenerative Medicine (MIRM)
and Executive Director, The Pittsburgh
Tissue Engineering Initiative (PTEI)
Darin Weber, Ph.D., Senior Consultant
BIOLOGICS CONSULTING GROUP
Frequency Program: If you personally attend three Strategic
Research Institute conferences in 2006 as a fee-paying
delegate, you will be credited 50% off the full registration
fee of third event. Please be sure to indicate that it is your
third event when registering so that your invoice may be
adjusted accordingly. Discounts cannot be combined.
will not be issued after this date. The registration fee may be
transferred to you or another member of your organization for
any Strategic Research Institute conference during the next
12 months. If you plan on sending a substitution in your place,
you must please notify us as soon as possible so that material
and preparations can be made. In the event of a conference
cancellation, Strategic Research Institute assumes no liability
for non-refundable transportation costs, hotel accommodations
or additional costs incurred by the registrants.
SUGGESTED DRESS: Business Casual
Hotel Accommodations:We have reserved a limited
block of rooms with the hotel at a special discounted rate
for our attendees. To secure your accommodations, please
contact the hotel BY September 18th, 2006 and be sure to
mention that you are a Strategic Research Institute delegate.
VENUE: Renaissance Pittsburgh Hotel
107 6th Street , Pittsburgh, PA 15222
Tel: 412-562-1200 - Fax: 412-992-2010
Web: marriott.com/property/propertypage/PITBR
To Register: Visit www.srinstitute.com/stemcells or Call 800-599-4950 / 212-967-0095

Monday October 16, 2006
7:15 - 8:00
Registration and Continental breakfast
8:00 - 8:15
Chair’s opening remarks
Doros Platika, M.D., Ph.D., President & CEO
PITTSBURGH LIFE SCIENCES GREENHOUSE
Dr. Alan Russell, Conference, Co-Chair, Director
McGowan Institute for Regenerative Medicine
(MIRM) and Executive Director, The Pittsburgh Tissue
Engineering Initiative (PTEI)
Stem Cells update
8:15-9:00
Keynote
Application of cellular therapy to the field of regenerative
medicine is one of the most promising and exciting areas of
biomedical research. Identification of new sources and types of
stem cells, discovery of “additional/unexpected” differentiation
pathways, along with advances in purification, culture, and tissue
engineering technologies are all contributing to an explosion of
research publications, initiation of clinical trials, and tremendous
public interest. The talks to be presented in this meeting reflect
the broad scope, the remarkable potential, and the challenges
that need to be overcome before cell-based regenerative
medicine can become the standard of care.
Shelly Heimfeld, Ph.D., Director
Cellular Therapy and Cell Processsing
Facilities
Associate Member, Fred Hutchinson Cancer
Research Center
President, the International Society of Cellular
Therapy
Discovery Cells
9:00 - 9:30
hESC-derived beta-islets for therapeutic
intervention in diabetes
Cell Therapy for the widespread treatment of diabetes is currently
limited by the lack of an unlimited safe supply of islet cells and a
means of delivering these cells without chronic immunosuppresion.
Novocell is committed to the development of a transformational
cell replacement product for the treatment of diabetes by
combining a clinically relevant cell encapsulation technology with
an unlimited supply of functional insulin secreting cells derived
from hESCs. Current progress towards these goals will be
discussed.
Alan Lewis, Ph.D., President & Chief Executive Officer
Novocell
9:30-10:00
Human ESC-derived cells for rescue of visual
function and repair of vascular damage
Embryonic stem cells promise to provide a well-characterized
and reproducible source of replacement tissue for human clinical
studies. Two early potential applications of this technology
are the use of human embryonic stem cell (hESC)-derived
retinal pigment epithelium (RPE) for the treatment of retinal
degenerative diseases such as macular degeneration and retinitis
pigmentosa, and the use of hESC-derived hemangioblasts for
vascular restoration of organs and limbs. Recent progress using
these cells to affect substantial functional and morphological
rescue in animals will be discussed.
Robert Lanza, M.D., Vice-President of Research and
Scientific Development
Advanced Cell Technology
10:00 -10:30
Bioreactor-actuated ovarian follicle maturation
Chemotherapy for girls with cancer can lead to infertility later
in life. Embryonic stem cell generation is dependent on a not
entirely safe process for collection of oocytes from adult women.
Both of these problems could be solved if it were possible, in
vitro, to convert immature ovarian follicles into functional oocytes.
Unfortunately, immature ovarian follicle culture results in follicle
death within days let alone oocyte generation. This presentation
will describe the first bioreactor that has been developed
specifically for maturation of immature follicles and will discuss
the results that have been obtained. The implication of the results
on safe stem cell derivation will be summarized.
Dr. Alan Russell, Conference, Co-Chair, Director
McGowan Institute for Regenerative Medicine
(MIRM) and Executive Director, The Pittsburgh Tissue
Engineering Initiative (PTEI)
10:30 -11:00
Networking break & Exhibitions
Discovery-Enabling materials
11:00 - 11:30
Driving Stem Cell Differentiation with a Novel
High Throughput System
Plasticell has developed a high throughput method for the
determination of complex protocols that can direct the differentiation
of embryonic stem cells. Pluripotent stem cells grown on
microscopic beads (microcarriers) are shuffled through many
thousands of different culture conditions, followed by phenotypic
screening to identify microcarriers bearing differentiated cells.
Using fluorescent labels added during the culture steps it is
possible to deduce the protocols that resulted in directed
differentiation. Since these are compatible with microcarriers,
the process is straightforwardly scaled up for manufacturing.
Yen Choo, Ph.D., Founder & CEO
Plasticell
11:30 - 12:00
Chemical and Functional Genomic Approaches
toward Regenerative Medicine
Under conditions of trauma or disease, the adult animal is able
to selectively re-activate the same developmental pathways used
during embryonic development to heal and regenerate tissue.
To Register: Visit www.srinstitute.com/stemcells or Call 800-599-4950 / 212-967-0095

Monday October 16, 2006
Since stem cells play an important role in regenerative medicine,
understanding their developmental pathways could open the
door for the treatment of a multitude of current diseases for
which few or no treatments currently exist. It is conceivable that
modern pharmacological approaches could drive the renewal of
parts of the human body—including the growth of neurons in the
brain and spinal cord, repopulation of diseased blood cells, and
eventually, perhaps, the re-growth of lost limbs. Recent advances
in stem cell technologies, such as stem cell-based phenotypic
and pathway-specific screens of synthetic compounds and RNAi,
have made it possible to identify both candidate drug targets and
small molecules that can be used to selectively control stem cell
fate. Such molecules will likely provide new insights into stem
cell biology, and may ultimately contribute to effective medicines
for tissue repair and regeneration.
John Hambor, Ph.D., Associate Research Fellow,
Genetically Modified Models Center of Emphasis
Pfizer Global Research and Development
12:00 - 1:30 Lunch
Pre-Clinical Development
1:30 - 2:00
Glial Progenitor Cells for Neurological Diseases
Human glial progenitor cells are being developed as therapeutics
for the treatment of demyelinating diseases. The process of
antibody based cGMP cell manufacture will be presented
along with product characterization methodologies for cells
sourced from fetal cadaveric tissue. In vivo studies in the
twitcher mouse, a lysosomal storage disorder model, and the
shiverer mouse, a general model for demyelinating diseases,
demonstrate that these glial progenitors engraft robustly, migrate
extensively and differentiate into astrocytes and myelin producing
oligodendrocytes. Additional studies in animal models will be
discussed.
James Campanelli, Ph.D., Director of Research
Q Therapeutics
2:00 - 2:30
Human Embryonic Stem Cell Derived
Oligodendroglial Progenitors for the Treatment of
Spinal Cord Injury
Demyelination contributes to loss of function following
spinal cord injury, and so a potential therapeutic strategy
involves replacing myelin forming cells. Here, we show that
transplantation of human embryonic stem cell (hESC) -derived
oligodendrocyte progenitors (OPCs) into adult rat spinal cord
injuries enhances remyelination and promotes recovery of motor
function. We hypothesize that hESC OPCs promote neural
repair and behavioral recovery through multiple mechanisms,
including transplant-mediated remyelination and transplantmediated
effects on endogenous cells. We present both efficacy
and safety data concerning the use of this cell population in
transplant regimes, and regulatory concerns regarding the
translation of stem cell technologies into human treatments.
Hans Keirstead, Ph.D., Associate Professor of Anatomy
and Neurobiology, Co-Director of the Stem Cell Research
Center
Reeve-Irvine Research Center
2:30 - 3:00
Novel Therapeutic Application of Universal Adult
Stem Cell Derived Myeloid Progenitor Cells
Neutropenia induced by chemotherapy, ablative conditioning
for hematopoietic transplantation or exposure to high doses of
radiation is frequently accompanied by significant morbidity and
mortality due to high susceptibility to infection. Cellerant’s CLT-
008 is a universal off-the-shelf cellular product that consists of
myeloid progenitors capable of producing mature myeloid cells
such as granulocytes, macrophages, platelets and erythrocytes
in vivo. Pre-clinical studies using mouse models have shown
that the myeloid progenitor cells prevent fungal and bacterial
infection in neutropenic mice and increase survival in allogeneic
transplantation. The results from these studies and the
development path for clinical evaluation will be discussed.
Ram Mandalam, Ph.D., Vice President, Pharmaceutical
Operations
Cellerant Therapeutics
3:00 - 3:30 Networking break & Exhibitions
Clinical Development
3:30 - 4:00
Cellular Therapies for the Treatment of Coronary
Ischemia
Arteriocyte is a clinical stage research and development company
focused on developing cellular therapies to treat ischemic
disease. The company will capitalize on the bench to bedside
expertise of its scientific founders to develop stem cell-based
therapies for ischemic diseases with an initial focus on coronary
applications. The clinical objective is “therapeutic angiogenesis”
or the generation of new blood vessels to replace those blood
vessels which no longer adequately supply a tissue. These cellular
therapies will eventually help patients suffering from a number of
ischemic conditions including coronary artery disease.
Don Brown, Chief Executive Officer
Arteriocyte
4:00 - 4:30
Clinical Development of Regenerative Medicinal
products in North America and Europe
Intercytex is a UK based Regenerative Medicine Company and
became operational in early 2000. It recently floated on the
London Stock Market’s AIM market and has facilities in the UK
and US. It currently has 4 products in clinical development in the
US and Europe and plans to launch its first product in 2007. The
company has its own licensed GMP manufacturing facility and
is beginning to set up a sales and marketing infrastructure. The
talk will discuss the clinical strategy adopted by the company,
how the changing regulatory environment on both continents
has influenced the company’s development and the results it has
obtained to date in Europe, Canada and the US.
Paul Kemp, Ph.D., Chief Scientific Officer
Intercytex
To Register: Visit www.srinstitute.com/stemcells or Call 800-599-4950 / 212-967-0095

4:30-5:00
Capitalizing on Endogenous Stem Cell
Populations
Stem Cell Therapeutics Corp. (SCT) is a Canadian company
focused on bringing to market therapeutics that utilize
endogenous stem cell populations to replace damaged, lost,
or diseased tissue. SCT’s first clinical program, termed NTx-
265, is based on a neuroregeneration strategy for treating the
functional and cognitive deficits that are inevitable following a
stroke. This program is currently in a Phase IIa clinical trial in the
United States. The NTx-265 therapeutic regimen utilizes two,
on-market pharmaceuticals that have been found to promote
endogenous neural stem cell proliferation and differentiation
into neurons. By repurposing these products, SCT has rapidly
advanced its stroke recovery program into the clinic. Additional
indications are being identified utilizing a similar approach.
Allen Davidoff, Ph.D., Vice President, Product
Development
Stem Cell Therapeutics Corp
5:00 - 5:30
Preclinical, Product, and Clinical Development of
Human Embryonic Stem Cell Based Therapies
Human embryonic stem cells (hESCs) can be differentiated
into any cell type and serve as a limitless source of cells for
the treatment of degenerative diseases. As one example of
the therapeutic potential of these cells, hESCs have been
differentiated into oligodendroglial progenitor cells which
can induce lesional repair and locomotor improvements upon
transplantation in animals with spinal cord injuries. To enable
translation to clinical development, extensive preclinical
safety studies and scaled cGMP manufacturing operations
are underway. Updates on our progress towards clinical
development will be discussed.
Jane Lebkowski, Ph.D., Senior Vice President Regenerative
Medicine
Geron Corporation
5:30-7:00 Cocktail reception
Call for Posters
Why should you present your research poster at the 6th Annual
Stem Cells & Regenerative Medicine Conference?
4 Your poster will be exposed to senior-level decision-makers,
research scientists, and clinicians involved in Stem Cells &
Regenerative Medicine from major pharmaceutical, biotech,
academic and government institutions.
4 Your poster abstract will be published in our conference
documentation book and the title of your poster will be published
on the conference website.
To be considered for a poster presentation, please contact Seth
Fritts at: 212-967-0095 x 256 or sfritts@srinstitute.com before
Friday September 22nd.
How to submit your poster presentation:
1. Please email your titled abstract to Seth Fritts at sfritts@
srinstitute.com
2. The abstract should include a title and be up to 1 page in
length. Include your name, title, company and full contact
information.
Tuesday October 17, 2006
7:15 - 8:00
Registration and Continental breakfast
New Technologies
8:00 - 8:30
Adult Multipotential Cells: Novel Sources, Novel
Uses
Aggregate Therapeutics Inc, was formed to commercialize
technologies from the labs of stem cell scientists within the
Stem Cell Network of Canada, a National Center of Excellence.
Aggregate Therapeutics will initially focus its efforts on
commercialization of cellular therapies for the large regenerative
medicine markets. Aggregate has identified novel technologies
based on multipotential cells derived from skin, pancreas and
retina, as well as genetically-modified cells from bone marrow.
The basic science and early preclinical data from the initial
multipotential cell development program will be presented.
Annemarie Moseley, Ph.D., M.D., Acting CEO
Aggregate Therapeutics
Chairman, REPAIR TECHNOLOGIES
8:30 - 9:00
Opportunities for adult stem cell technology
in high throughput content screening (HTS) of
pharmaceutical compounds
(Please see website for abstract)
Sitta Sittampalam, Head, Lead Optimization Biology
Eli Lilly
9:00 - 9:30
Therapeutic Utility of Small Molecule Stem Cell
Modulators
(Please see website for abstract)
Kyle Chan, Senior Director, Discovery Research
Celgene
9:30 - 10:00
Human embryonic stem cells and predictive
toxicology: a novel systems biology approach
The predictive toxicity of chemicals to humans is determined
largely in animal models. These models have limitations to
emulate human response Our laboratory examines the ability
of human embryonic stem cells to predict toxic outcomes of
chemicals during early human development. We seek biomarkers
of toxic response using a systems biology approach that
integrates molecular and functional cellular responses. We
have preliminary evidence that toxicity in this human in vitro
model is consistent with in vivo animal studies at the molecular
level. These initial studies provide proof of concept for future
application of hES cell technology in predictive toxicity of
chemicals.
Gabriela Cezar, DVM, Ph.D., Assistant Professor,
Developmental Biology
UW-Madison, Wisconsin Stem Cell Research
Program
10:00 - 10:40
Networking break & Exhibitions
To Register: Visit www.srinstitute.com/stemcells or Call 800-599-4950 / 212-967-0095

Tuesday October 17, 2006
Commercialization and Investment Opportunities
10:40-11:00
New Model for successful commercialization
in life sciences - The Pittsburgh Life Sciences
Greenhouse Model
The Pittsburgh Life Sciences Greenhouse (PLSG) was created
as part of a larger plan to ensure continued growth in the life
sciences in Pennsylvania. Since its inception, the PA Greenhouse
Initiative has established a national and international reputation.
The PA Greenhouse Initiative has been cited as one of only two
university/industry funding programs focused solely on the life
sciences in the U.S., and it has become a national model for
state funding of early stage risk capital in the life sciences. The
PLSG has taken the initiative one step further and is working on
programs to address later stage commercialization opportunities
for the region. This presentation will outline the PLSG’s programs,
successful initiatives, and collaborative efforts that are in place to
commercialize technology in Pittsburgh in order to create a selfsustaining
life sciences industry.
Doros Platika, M.D., Ph.D., President & CEO
PITTSBURGH LIFE SCIENCES GREENHOUSE
11:00 - 11:20
Outlook on the Stem Cell Sector: A Perspective
from Wall Street
The stem cell space has rapidly advanced from relative
obscurity to the forefront of innovative therapeutic development
addressing areas of large unmet need. The “driving force” for the
advancement of the future of stem cells remains biotechnology
companies willing to take large risks. In our view, the “fuel” to
drive the development of innovative products remains scientific
knowledge and investor dollars. This presentation will address
several crucial aspects of the stem cell universe from the point of
view of Wall Street including understanding the investor mindset,
the relative valuation metrics and factors that drive market value of
stem cell companies, as well as the potential to “time” the market
for funding opportunities.
Reni Benjamin, Ph.D., Senior Biotechnology Analyst
Rodman & Renshaw
11:20 - 11:40
A UK VC perspective investing in stem cell
therapeutics
The presentation aims to highlight the current status and
impact of the EU regulatory framework, funding sources (public
(including government), private and pharma), IP, business models
and infrastructure logistics.
Cathy Prescott, DPhil, Science Director
Avlar BioVentures
11:40-12:00
Venture Capital perspective
Mr. Bonfiglio is the Managing Director of Proteus Venture Partners,
a newly formed venture fund that will be investing solely in
regenerative medicine companies. Mr. Bonfiglio will review the
current funding environment for regenerative medicine companies
– where we are, how we got here, and what the future holds
from funding sources. Mr. Bonfiglio also will discuss where
regenerative medicine companies can find funding and the typical
deal structures for companies that are successful in securing
funding.
Gregory Bonfiglio, Managing Director
Proteus Venture Partners
12:00 - 1:15 Lunch
1:15 - 2:00
Commercialization and Investment Opportunities-
Panel discussion
Moderator:
Doros Platika, M.D., Ph.D., President & CEO
PITTSBURGH LIFE SCIENCES GREENHOUSE
Panelists:
Reni Benjamin, Ph.D., Senior Biotechnology Analyst
Rodman & Renshaw
Gregory Bonfiglio, Partner
Proteus Venture Partners
Cathy Prescott, DPhil, Science Director
Avlar BioVentures
Regulatory
2:00 - 3:30
Regulatory issues in Stem Cells & Regenerative
Medicine
What are some of the regulatory challenges in taking your stem
cell-based/regenerative medicine product to clinic? The answer
largely depends on:
1. The complexity of your product (for example, does it consists
of cells only, or include a biomaterial?)
2. The source of the tissue used ( for example, embryonic, fetal,
adult, xenogeneic)
3. The development of analytical tools for testing and
characterization of stem cell component (for example, cellspecific
biomarkers, unique genomic or proteomic profiles).
The planned clinical indication, severity of disease and route
of administration.
4. The availability of relevant preclinical animal models of
disease (for example, is a small animal model sufficient to
assess safety or will larger animals be needed?)
This panel will consist of members who have ‘real world’
experience with one or more of these issues along with
regulatory experts who can share their experiences. Active
participation from the audience is expected and encouraged and
intended to answer your questions and foster an exchange of
ideas.
Donald Fink, Jr., Ph.D., Cell Therapy Branch
Office of Cellular, Tissue and Gene Therapies
Center for Biologics Evaluation and Research/US-FDA
Darin Weber, Ph.D., Senior Consultant
The Biologics Consulting Group
3:30 End of conference
To Register: Visit www.srinstitute.com/stemcells or Call 800-599-4950 / 212-967-0095

Special Thanks to our Sponsors
PLATINUM LEAD SPONSOR
The Pittsburgh Life Sciences
Greenhouse (PLSG) is a strategic
economic development initiative.
Our goal is to grow southwestern
Pennsylvania’s region to become a
premier national and international
center for the Life Sciences. It is a collaborative effort
including key government, university, industry and economic
development organizations that will result in a critical mass
of bioscience companies, jobs and research infrastructure.
The PLSG initiative is being built on a powerful base of
advanced research and healthcare capabilities led by the
University of Pittsburgh, Carnegie Mellon University and the
UPMC Health System. www.pittsburghlifesciences.com
Progenitor Cell Therapy (PCT)
is a client-based cell therapy
services company that supports the
development and commercialization
of cellular therapies. PCT provides
cGMP-compliant cell manufacturing and consulting services
that address regulatory, financial, technical, process, and
quality system strategies. Services include a full spectrum
of support including process and product development,
consulting, validation, due diligence evaluations, tissue
collection, processing, and storage, product manufacturing,
distribution and transportation.
BioSpherix Ltd. specializes in
productive biological atmospheres.
Featured on exhibit will be a unique
new STEM CELL CLOSED-SYSTEM
INCUBATOR which offers (1) better expansion of stem
cell cultures, (2) unprecedented new ability to manipulate
stem cell phenotype, and (3) the first clear critical path to
cGMP-compliant production of stem cells for clinical trials
and therapeutic use. Not only can it accelerate stem cell
research and development by large factor, but as a practical
and economical new alternative to bricks-and-mortar cleanrooms,
it should save huge amounts of money and time
getting new stem cell therapies into the clinic. No other
system offers so much for so little. Please stop by and pick
up a brochure!
Epiontis GmbH Berlin, Germany
Epiontis GmbH is an innovative
biotechnology company that exploits
the biological phenomenon of DNA
methylation as an analytical tool in Regenerative Medicine.
Epiontis provides QC tests that determine identity, purity
and potential contaminations of cell products (EpiTest kits) and
HTS screens to identify new growth factors (EpiScreen).
Epiontis proprietary DNA-methylation analysis is more
universal, sensitive and robust than conventional analysis
methods such as cDNA arrays, enzyme assays and
immunological test. www.epiontis.com
Thank you to our Media Partners
Sponsor / Exhibitor Opportunities
An Outstanding Business Development Opportunity:
By becoming a Sponsor and/or Exhibitor at this executive
conference, your company or firm will join some of this industry’s
leading decision-makers. Since 1993 the Strategic Research
Institute has specialized in organizing executive conferences (not
trade shows). Consequently, our clients who attend include only the
most senior decision-makers in this business space.
Pre-Event Exposure:
Before each conference, the event brochure and other marketing
efforts reach a very targeted group of senior decision-makers;
and by partnering with SRI in presenting this conference, your
company brand and a brief description of your products or services
may be included in a pre-event marketing campaign that reaches
approximately 25,000 to 35,000 targeted executives.
Face-to-face Business Development Opportunities:
At the conference itself, there are only a limited number of
sponsorship and exhibit opportunities. For example, you may
choose to sponsor one of several informal networking functions
such as the morning breakfast buffet, mid-morning or mid-afternoon
refreshment break, or a luncheon or evening networking reception.
All sponsorships may include an approximately 8’ x 10’ exhibit
space. If your sponsorship is confirmed early in the development of
the conference agenda, a speaking role on one of the conference
sessions or panels may be included if appropriate.
For more information about how your company can take advantage
of this exclusive gathering of your potential customers, contact
Hank Woji at hwoji@srinstitute.com or 719-290-8836.
To Register: Visit www.srinstitute.com/stemcells or Call 800-599-4950 / 212-967-0095

Present A Poster
See Inside for Details
6th Annual
Stem Cells&
Regenerative Medicine
The Annual Standard in Industry-Focused Applications of Stem Cell Research
October 16-17, 2006 • Renaissance Pittsburgh Hotel • Pittsburgh, PA
6th Annual Stem Cells & Regenerative Medicine
REGISTRATION FORM
333 Seventh Avenue, 9th Floor, New York, NY 10001
Tel 212-967-0095 or 1-800-599-4950 • Fax 212-967-8021
q $1195 Early bird: until Friday September 1, 2006; $1495
After September 1st and before October 6th; $1595 after
October 6th
q $695 Academic/Government/Nonprofit
www.srinstitute.com/stemcells
o Payment enclosed o Bill my company
Charge my: o American Express o Visa o MasterCard
o Diners Club o Discover
Card#________________________________________________
Expiration Date: Month Year ______________________________
Name (as shown on card)_________________________________
Name (please print)________________________________
Title______________________________________________
Company_________________________________________
Address___________________________________________
333 Seveth Avenue, 9th Floor
New York, NY 10001
Return Service Requested
Presorted
First Class
U.S. Postage
PAID
Burlington, VT
Permit No. 21
City/State/Zip Code_______________________________
E-Mail____________________________________________
Phone/Fax_________________________________________
cs369